Alterity.png
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
April 29, 2024 07:25 ET | ALTERITY THERAPEUTICS LIMITED
–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
Regeneron Logo.jpg
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024 07:00 ET | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the...
logo.jpg
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
April 29, 2024 07:00 ET | Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets...
MoneyHero_Logo.png
MoneyHero Group Reports Fourth Quarter and Full Year 2023 Results
April 29, 2024 07:00 ET | MoneyHero Limited
MoneyHero Group Reports Fourth Quarter and Full Year 2023 Results
GRTS_2021_logoupdate_color.jpg
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
April 29, 2024 07:00 ET | Gritstone bio
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Cullinan_Logo_1200x628.png
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
April 29, 2024 07:00 ET | Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the...
Breckenridge Brewery has a fresh new IPA for the outdoor enthusiasts
Breckenridge Brewery Introduces New West Coast Style IPA ‘Ridge Runner’
April 29, 2024 07:00 ET | Tilray Brands, Inc.
Breckenridge Brewery Launches New Ridge Runner IPA inspired by the untamed beauty of Colorado’s trails and adventurous outdoor lifestyle behind the brand.
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2024 Financial Results
April 29, 2024 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct...
AVIR.png
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
April 29, 2024 07:00 ET | Atea Pharmaceuticals, Inc.
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
ALLARITY Full Color RGB 2023JUN07.png
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024 07:00 ET | Allarity Therapeutics, Inc.
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...